News

Challenges Faced by FirstFarms Due to Low Market Prices

Challenges Faced by FirstFarms Due to Low Market Prices

FirstFarms Faces Financial Hurdles Amid Price Challenges

Unsatisfactory interim result – impacted by low prices

FirstFarms A/S has released its interim financial report for the years first nine months, reflecting a challenging analysis with a result of -6 million DKK. Despite reasonable yields across fields this year, overall prices have not met expectations.

The significant issue during Q2 and Q3 stemmed from an outbreak of foot and mouth disease (FMD), which greatly affected both the output and finances, particularly hindering milk production revenue.

The Board of Directors and Management have thoroughly reviewed the unaudited interim financial accounts for the specified period.

Main Financial Figures

During this reporting period, FirstFarms has achieved the following:

  • Turnover of 284 million DKK (compared to 327 million DKK in 2024)
  • EBITDA reaching 72 million DKK (down from 86 million DKK in 2024)
  • EBIT is recorded at 21 million DKK (decreasing from 41 million DKK)
  • Result before tax stands at -5 million DKK (declined from 13 million DKK last year)

The significant decrease in turnover this year—down by 13 percent—was primarily influenced by reduced milk sales and a downturn in pig prices. Consequently, the results before tax have also seen a decline, greatly attributed to the ongoing effects of FMD and a negative revaluation of stock due to low market prices.

Although the group's harvest yields are satisfactory, the unfavorable pricing environment has heavily influenced the overall results for the first three quarters.

Co-CEO Michael Hyldgaard expressed concerns regarding the financial performance: "We are not satisfied with the result for the first 9 months. We have been affected by lack of milk production because of FMD, but low and decreasing prices for pigs and crops have also had a major impact on the result."

Status on FMD and Recovery Efforts

In relation to the FMD outbreak confirmed earlier in the year, significant remediation efforts have been put in place since the onset of the disease. Following the necessary culling of cattle, the farm has undergone thorough cleaning and disinfection processes. By early September, 36 test animals were introduced, all of which tested negative for the disease. Officially being declared free of FMD on September 24 signals a positive turning point for FirstFarms.

Following this declaration, plans for optimization and upgrades to the farm commenced, resulting in the anticipated introduction of livestock by December 2025. Additionally, FirstFarms has acquired 1,900 pregnant heifers and cows, which showcases a proactive approach to restoring production levels.

Co-CEO Søren Bredvig highlighted the dedication of employees in overcoming the challenges of the FMD outbreak, leading to expectations of resuming milk production to pre-FMD levels by the second half of 2026.

Future Expectations for 2025

Due to the repercussions of the FMD outbreak, FirstFarms has revised expectations for the financial year downwards by 45 million DKK. The herd was insured for 31 million DKK, with 60% received by the end of Q3. Remaining payouts from the insurance policy are anticipated before year-end, although operational losses remain uninsured.

Additionally, FirstFarms has pursued regional subsidies to support investments in livestock and mitigate other outbreak-related costs. The estimated subsidy is expected to be between 50-60 million DKK and will significantly impact earnings in 2025, contingent on maintaining the herd for five years.

Looking ahead, FirstFarms anticipates:

  • EBITDA between 60 - 90 million DKK
  • EBIT fluctuating between -10 - +20 million DKK

There is optimism regarding slightly increasing pig and crop prices for the remainder of the year, with expectations of a market turnaround toward higher prices as Q4 continues.

Best regards,
FirstFarms A/S

Frequently Asked Questions

What were FirstFarms' primary challenges in this report?

The main challenges included low market prices for pigs and the impact of foot and mouth disease on production and sales.

How did the FMD outbreak affect FirstFarms’ operations?

The FMD outbreak led to significant reductions in milk production, culling of livestock, and disruptions in sales revenue.

What measures has FirstFarms taken to recover from FMD?

They have implemented extensive cleaning, introduced test animals, and begun farm upgrades, expecting to resume normal milk production levels by mid-2026.

What are FirstFarms’ financial forecasts for 2025?

They project an EBITDA between 60 and 90 million DKK and an EBIT ranging from -10 to +20 million DKK.

What strategic steps is FirstFarms taking moving forward?

FirstFarms is focusing on optimizing operations, acquiring livestock, and anticipating a rebound in prices to enhance financial performance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Mobilize for Action Against Organon & Co. (OGN) Claims

Updated Category News Views 248

Mobilizing for Justice: Organon & Co. Class Action Lawsuit Overview Recent developments have drawn serious attention to Organon & Co. (NYSE: OGN), as investors set their sights on a class action lawsuit aimed at seeking justice for significant financial losses incurred. The legal proceedings are a reaction to purported misleading statements made by the company’s...

Continue Reading
Humana's 2024 Third Quarter Results Show Financial Resilience

Updated Category News Views 107

Humana Reports Third Quarter Financial Results for 2024 Humana Inc. (NYSE: HUM) has recently disclosed its consolidated financial results for the third quarter of 2024, highlighting a comprehensive overview of its performance compared to the previous year. Despite prevailing challenges within the healthcare sector, the organization showcased solid financial resilience and...

Continue Reading
CobbleStone Joins Civic Marketplace for Easy Gov't Procurement

Updated Category News Views 21

CobbleStone Software Goes Digital with Civic Marketplace Sometimes in this tech-driven world, it feels like the old-school bureaucratic processes just can't keep up. Enter CobbleStone Software, a name that's ringing bells in the halls of government offices with a neat little trick up its sleeve: integrating its contract management platform into the Civic Marketplace. It's...

Continue Reading
Shineco Inc Faces Stock Challenges Amid Recovery Efforts

Updated Category News Views 186

Shineco Inc Stock Experiences Significant Decline Shineco Inc (SISI) has reached a concerning milestone as its stock plummets to a 52-week low at $1.92. With a market capitalization of only $3.64 million, this dip reveals ongoing issues within the company's financial landscape. Analysts have pegged its financial health score as 'WEAK', bringing to light several risk...

Continue Reading
Epsilon Energy Reflects on Strategic Acquisitions in Oil and Gas

Updated Category News Views 254

Epsilon Energy’s Latest Strategic Acquisition Epsilon Energy Ltd. (NASDAQ: EPSN), a prominent player in North American onshore natural gas and oil production, has completed significant acquisitions, marking an important chapter in the company’s expansion strategy. Through the recent purchase of Peak Exploration and Production LLC and Peak BLM Lease LLC, referred to as...

Continue Reading